Studies on Liv.52 in hepatic disorders


Part II: Indian Childhood Cirrhosis and Miscellaneous Conditions — 97 Cases
Sharma, N.L., M.D., D.C.H. (Lond.), F.R.S.T.M.&H. (Eng.), D.T.M., D.P.H. (Cal.), Professor and Head of the Department of Pediatrics
Lahori, U.C., M.D., D.C.H., Research Scholar and
Mehta, S.K., B.Sc., M.B.,B.S., D.C.H., Research Scholar, King George’s Medical College, Lucknow, U.P., India.

In Part I of their Paper the Authors reported on 58 Cases of Viral Hepatitis. Of these 32 cases were treated with Liv.52 and supportive therapy while 26 cases served as controls and received only supportive therapy. These 58 cases were in Group I of their study. Findings in the remaining 97 cases are presented in Part II of the Paper.

GROUP II

Indian Childhood Cirrhosis — 41 cases

This group consisted of 41 cases of Indian childhood cirrhosis. The diagnosis of these cases was made on the basis of criteria laid down by the Liver Disease Sub-Committee Report of I.C.M.R. (1955) as under:

Stage I: A firm liver with a rather sharp edge with or without palpable spleen and mild constitutional symptoms.

Stage II: Progressive deterioration, hepatosplenomegaly, distended abdomen, slight icterus, slight oedema and ascites may be present. Child is irritable and loses weight.

Stage III: Marked deterioration with signs and symptoms of hepatocellular failure like hepatosplenomegaly, oedema, ascites, jaundice, haematemesis and/or malena.

Only the early cases of Stage I and Stage II of Indian Childhood Cirrhosis were included in the present study. Stage III cases were not included in the present study. Thirty two cases were in Stage I and 9 in Stage II. In every case, detailed present history, past history, family and dietetic factors were noted and liver function tests were done. These cases were divided into two sub-groups:

Sub-Group A: Liv.52 with minerals and vitamins – 21 cases.

Sub-Group B: Given only minerals and vitamins – 20 cases.

Table V

Signs and Symptoms

Total No. of Infantile Cirrhosis = 41

No. with positive Signs & Symptoms

Percentage

1.

Fever

21

51.22

2.

Anorexia

30

73.17

3.

Vomiting

3

7.31

4.

Diarrhoea

28

68.29

5.

Constipation

10

24.39

6.

Abdominal distension

35

85.36

7.

Jaundice

3

7.31

8.

Irritability

32

78.04

9.

Oedema

Nil

10.

Underweight

34

82.92

11.

Anaemia

15

36.58

12.

Lymphadenopathy

4

9.75

13.

Liver size –

Up to 3 cm

28

68.29

3 to 5 cm

13

31.70

14.

Spleen –

Up to 3 cm

34

82.92

3 to 5 cm

7

17.07



Table VI: Improvement of clinical features in cases of infantile cirrhosis receiving Liv.52 as compared to controls

Signs and Symptoms

Improvement in % of cases with Liv.52

Improvement in % of cases of controls

1.

Irritability (32)

75%

(15/20)

33%

(4/12)

2.

Anorexia (30)

90%

(16/18)

16.6%

(2.12)

3.

Enlarged liver (41)

80%

(16/20)

55%

(11/20)

One patient left against medical advice.


OBSERVATIONS AND RESULTS

In Group II — Infantile cirrhosis of liver – 41 cases

The majority of cases were between 1 to 3 years: 34 males and 7 females. Positive family history of infantile cirrhosis was obtained in 14 cases only (34.12%).

The Liv.52 treated group showed much better clinical response than the control group in both signs and symptoms and the progress of the clinical course.

Cases which received Liv.52 showed improvement in general health and well-being along with gain in weight in 17 out of 21 cases (81).

Seventy five per cent of cases showed early improvement of irritability compared with 33% in the control group.

Ninety per cent showed improvement in appetite compared to 16.6% in the control group.

Cases in the Liv.52 group showed regression in liver size in about 80% of cases (16 out of 20 cases) along with clinical remission (Table VII). There was improvement in liver function tests though they could not be done in every case (Tables VIII and IX).

Table VII: Clinical course in infantile cirrhosis treated with Liv.52 as compared to controls

Groups

Total No. of cases

Left against medical advice

Deaths

Progression to III stage

Clinical remission

Therapeutic group (Liv.52)

21

1

1

3

16

Control group

20

Nil

1

8

11



Refference: http://www.himalayahealthcare.com/pdf_files/liv226.pdf
free delivery Liv 52
Copyrights © 2009 healthyliver.co.uk